Announcements - OBI Pharma 台灣浩鼎

2019.Aug.31

OBI Pharma Announces U.S. FDA Clearance of IND Application for a Phase I/II Study of its Antibody-Drug Conjugate (ADC) targeted cancer therapy, OBI-999

2019.Aug.12

Board of Directors Approved the Change of Financial Officer and Acting Spokesperson

2019.Aug.03

IND Phase I/II Human Clinical Trial Application of Globo-H Antibody-Drug Conjugate, OBI-999, submission to FDA

2019.Jul.31

Announcement on Change of Financial Officer and Acting Spokesperson

2019.Jul.29

Subsidiary AP Biosciences and Tasly Biopharmaceuticals Signed Cooperative Development and Authorized Agreement of New Antibody Drug

2019.Jul.22

Announcement on the Change of Spokesperson

2019.Jul.22

Announcement of New CEO

2019.Jul.22

Announcement of 3rd Audit Committee Members

2019.Jul.22

Announcement of 4th Payroll Committee Members

2019.Jul.11

Taiwan Shilin District Court appeals against the acquittal of Mr. Michael Chang and five other executives’insider trading case

News

Latest News

Events

Latest events